3m11: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:3m11.jpg|left|200px]]
-<!--
-The line below this paragraph, containing "STRUCTURE_3m11", creates the "Structure Box" on the page.
-You may change the PDB parameter (which sets the PDB file loaded into the applet)
-or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
-or leave the SCENE parameter empty for the default display.
--->
 {{STRUCTURE_3m11|  PDB=3m11  |  SCENE=  }}
 ===Crystal Structure of Aurora A Kinase complexed with inhibitor===
+{{ABSTRACT_PUBMED_20550212}}
+==Function==
-<!--
+[[http://www.uniprot.org/uniprot/STK6_HUMAN STK6_HUMAN]] Mitotic serine/threonine kinases that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for initial activation of CDK1 at centrosomes. Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. Regulates KIF2A tubulin depolymerase activity. Required for normal axon formation. Plays a role in microtubule remodeling during neurite extension. Important for microtubule formation and/or stabilization. Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and stabilizing p53/TP53. Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity. Necessary for proper cilia disassembly prior to mitosis.<ref>PMID:9606188</ref> <ref>PMID:11039908</ref> <ref>PMID:11551964</ref> <ref>PMID:12390251</ref> <ref>PMID:13678582</ref> <ref>PMID:14523000</ref> <ref>PMID:15147269</ref> <ref>PMID:14990569</ref> <ref>PMID:15128871</ref> <ref>PMID:14702041</ref> <ref>PMID:15987997</ref> <ref>PMID:18056443</ref> <ref>PMID:17604723</ref> <ref>PMID:17360485</ref> <ref>PMID:18615013</ref> <ref>PMID:19812038</ref> <ref>PMID:19351716</ref> <ref>PMID:19668197</ref> <ref>PMID:19357306</ref> <ref>PMID:20643351</ref> <ref>PMID:17125279</ref>
-The line below this paragraph, {{ABSTRACT_PUBMED_20550212}}, adds the Publication Abstract to the page
-(as it appears on PubMed at http://www.pubmed.gov), where 20550212 is the PubMed ID number.
--->
-{{ABSTRACT_PUBMED_20550212}}
 ==About this Structure==
@@ Line 22: / Line 10: @@
 ==Reference==
-<ref group="xtra">PMID:20550212</ref><references group="xtra"/>
+<ref group="xtra">PMID:020550212</ref><references group="xtra"/><references/>
 [[Category: Homo sapiens]]
 [[Category: Non-specific serine/threonine protein kinase]]
@@ Line 30: / Line 18: @@
 [[Category: Wu, J S.]]
 [[Category: Wu, S Y.]]
+[[Category: Atp-binding]]
+[[Category: Aurora kinase inhibitor]]
+[[Category: Cell cycle]]
+[[Category: Cytoskeleton]]
+[[Category: Kinase]]
+[[Category: Nucleotide-binding]]
+[[Category: Phosphoprotein]]
+[[Category: Serine/threonine-protein kinase]]
+[[Category: Structure-based drug design]]
+[[Category: Transferase]]
+[[Category: Transferase-transferase inhibitor complex]]
+[[Category: X-ray co-crystal analysis]]